comparemela.com

Latest Breaking News On - Cullinan oncology - Page 21 : comparemela.com

Analyzing Cidara Therapeutics (NASDAQ:CDTX) & Cullinan Oncology (NASDAQ:CGEM)

Cidara Therapeutics (NASDAQ:CDTX – Get Rating) and Cullinan Oncology (NASDAQ:CGEM – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current ratings […]

San-diego
California
United-states
Cambridge
Cambridgeshire
United-kingdom
Massachusetts
H-shaw-warren
Kevinm-forrest
Cullinan-pearl-corp
Cullinan-oncology-inc

Cullinan: Trading Way Below Cash

Cullinan Oncology (NASDAQ:CGEM) is a cancer focused drug developer with a mid stage pipeline. Their approach is to develop differentiated molecules with…

Cullinan-oncology
News
Ggregator
Reaking-news
Uration
Media

Harbour BioMed Reports Full Year 2022 Financial -2-

DJ Harbour BioMed Reports Full Year 2022 Financial Results EQS Newswire / 03/04/2023 / 12:10 UTC+8 Harbour BioMed Reports Full Year 2022 Financial Results CAMBRIDGE, Mass.; Suzhou, China; Rotterdam

China
Netherlands
Australia
Shanghai
Suzhou
Jiangsu
Hong-kong
Boston
Massachusetts
United-states
Cambridge
Cambridgeshire

Harbour BioMed Reports Full Year 2022 Financial Results

/PRNewswire/ Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and.

Netherlands
Australia
Suzhou
Jiangsu
China
Shanghai
Cambridge
Cambridgeshire
United-kingdom
Boston
Massachusetts
United-states

Cullinan Oncology's (CGEM) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cullinan Oncology (NASDAQ:CGEM – Get Rating) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $50.00 price objective on the stock. Separately, Morgan Stanley dropped their price objective on Cullinan Oncology from $27.00 to $19.00 and set an overweight […]

United-states
Nisa-investment-advisors
Barclays-plc
Morgan-stanley
Annandale-capital
Cullinan-oncology-inc
Tang-capital-management
Cullinan-oncology
Get-rating
Investment-advisors
Capital-management

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.